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Chronic venous insufficiency is associated
with increased platelet and monocyte
activation and aggregation
Craig C. Powell, MD, Michael J. Rohrer, MD, Marc R. Barnard, MS, Brian
D. Peyton, MD, Mark I. Furman, MD, and Alan D. Michelson, MD, Worcester,
Mass
Purpose: This study assessed whether the increased numbers of platelet-monocyte aggre-
gates observed in patients with venous stasis ulceration (VSU) represent a response to
dermal ulceration or if it is a condition associated with underlying chronic venous insuf-
ficiency (CVI). We also analyzed the expression of CD11b in patients with CVI to deter-
mine whether leukocyte activation, known to occur in VSU, is a precursor of or a
response to ulceration.
Methods: Patients with varying classes of CVI (n = 24) and healthy control subjects (n =
15), whose status was documented by means of duplex scanning, stood upright and sta-
tionary for 10 minutes. Two aliquots of blood, drawn from a distal leg vein and an ante-
cubital fossa vein, were incubated with either buffer or one of three platelet agonists.
After fixation, these samples were further incubated with fluorescent-labeled monoclon-
al antibodies (f-MoAb) specific for CD14 (monocytes) and CD61 (platelets). The acti-
vated leukocyte assay was performed by incubating another aliquot of the blood samples
with f-MoAb specific for CD11b and CD14. All samples were evaluated by means of
flow cytometry. 
Results: We observed significantly more platelet-monocyte aggregates throughout the cir-
culation in patients with CVI than in control subjects (29% vs. 8%; P < .0002).
Furthermore, patients with CVI formed significantly more of these aggregates in
response to all platelet agonists than did control subjects. There were no significant dif-
ferences between baseline numbers of aggregates or response to agonists in patients who
had CVI with (n = 10) or without (n = 14) ulceration. Patients with CVI had more cir-
culating platelet-neutrophil aggregates than control subjects (7.2% vs. 3.6%; P = .05). The
addition of platelet agonists to the blood of patients with CVI resulted in more platelet-
neutrophil aggregates than in control subjects. Monocyte CD11b expression was higher
in patients with CVI than in control subjects (7.5 vs. 3.7; P < .01), with no differences
noted in CD11b expression between patients with or without ulceration. Neutrophil
CD11b expression was low and similar in control subjects and patients with CVI.
Conclusion: All classes of CVI are associated with significantly increased percentages of
platelet-monocyte aggregates and increased percentages of platelet-neutrophil aggregates
throughout the circulation. The presence of more of these aggregates and the increased
propensity to form aggregates in the presence of platelet agonists in all classes of CVI
suggests an underlying state of platelet activation and increased reactivity that is inde-
pendent of the presence of ulceration. The increased expression of monocyte CD11b
throughout the circulation in all classes of CVI suggests that although systemic mono-
cyte activation occurs in CVI, its presence is independent of VSU as well. (J Vasc Surg
1999;30:844-53.)
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It is generally accepted that the fundamental
derangement in patients with chronic venous insuf-
ficiency (CVI) is sustained venous hypertension,
which results from valvular incompetence, outflow
obstruction, calf muscle dysfunction, or a combina-
tion of these.1 It is not yet known why a small sub-
set of patients with CVI progresses to the develop-
ment of stasis ulceration. At present, the most
accepted hypothesis regarding the development of
venous stasis ulceration (VSU) is the white cell trap-
ping theory,2 which postulates that activated leuko-
cytes sequestered within the microcirculation of
affected extremities release proteolytic enzymes with
resultant endothelial damage, fibrin cuff deposition,
and localized tissue ischemia and necrosis.
The role of activated leukocytes in the develop-
ment of VSU has been studied by many authors,
most of whom have concluded that monocytes are
the leukocyte involved in the development the most
severe clinical stage of CVI.3-5 Despite these obser-
vations, the underlying stimulus for leukocyte acti-
vation has yet to be elucidated. In fact, some authors
have questioned whether the ulcer itself might be
responsible for the activation of leukocytes that has
been observed in patients with VSU.3
Platelets, when activated, form aggregates with
other platelets (homotypic aggregates), as well as
with monocytes and neutrophils (heterotypic aggre-
gates), but not lymphocytes.6 Our laboratory has
shown that patients with VSU have increased
platelet-monocyte aggregation in systemic venous
blood.7 The primary objective of this study was to
determine whether this increase in circulating
platelet-monocyte aggregates is a result of CVI or if
it is an inflammatory response to dermal ulceration.
We also studied platelet-neutrophil aggregates in
CVI to better understand the role, if any, these het-
erotypic aggregates might play in this disease. 
The final part of our study was an evaluation of
the degree and distribution of monocyte and neu-
trophil activation in patients with various degrees of
CVI, as reflected by their surface expression of the
endothelial adhesion molecule CD11b. We attempt-
ed to determine whether, like heterotypic aggre-
gates, the presence of more of these cells in VSU is
a response to or a precursor of active ulceration. 
MATERIALS AND METHODS
The study population consisted of 24 patients
with CVI and 15 healthy individuals with normal
findings on lower-extremity duplex examinations
who served as control subjects. None of the patients
enrolled in this study participated in our earlier
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work.7 Within the group of patients with venous
insufficiency, nine patients had active ulceration, and
one patient had a recently healed ulcer. The remain-
ing 14 patients had varying clinical degrees of
venous insufficiency. In addition to their physical
findings, 21 of the 24 patients had objective confir-
mation of venous insufficiency by means of duplex
sonography scanning (Hewlett-Packard Sonos
5500). Patients were excluded when they had evi-
dence of active infection or any associated inflamma-
tory medical condition (eg, connective tissue dis-
ease, known malignancy). All study participants had
palpable pedal pulses and no evidence of arterial
insufficiency. The demographics of the study popu-
lation are listed in Table I.
Informed consent was obtained from all study par-
ticipants. The study was approved by the Committee
for the Protection of Human Subjects in Research at
the University of Massachusetts Medical Center.
All study participants were asked to stand
upright and stationary for 10 minutes to induce
lower-extremity venous hypertension. Blood was
drawn into citrated tubes from the greater saphe-
nous vein at the ankle (or a distal varix when active
ulceration precluded such a venipuncture or the vein
had been surgically removed) and an antecubital
fossa vein. Immediately thereafter, 20 m L of this
fresh, whole blood was incubated (22°C, 10 min-
utes) with 20 m L modified HEPES-Tyrode’s (HT)
buffer (137 mmol/L NaCl, 2.8 mmol/L KCl, 
1 mmol/L MgCl2, 12 mmol/L NaHCO3, 0.4
mmol/L Na2HPO4, 0.35% bovine serum albumin,
10 mmol/L HEPES, 5.5 mmol/L glucose; pH =
7.4), 15 m L of the peptide glycyl-L-prolyl-L-arginyl-
L-proline (GPRP) to inhibit fibrin polymerization
and sample clotting8 and 10 m L of either modified
HT buffer (control) or a platelet agonist (epineph-
rine 10 m mol/L, ADP 0.5 m mol/L, or thrombin
receptor activating peptide [TRAP] 5 m mol/L).
Thrombin (1 U/mL) was added to a final sample as
a positive control. Fixation with 1% formaldehyde in
Hanks balanced saline solution (22°C, 10 minutes)
was then performed. Samples were diluted 10-fold
with distilled H2O and incubated an additional 10
minutes to allow lysis of the erythrocytes. Another
0.5 mL HT buffer was added to the samples, fol-
lowed by centrifugal washing for 5 minutes at 500 g.
All the supernatant except 20 m L was discarded, and
the remaining pellets were incubated (22°C, 20
minutes) with 5 m L each of an anti-CD14 mono-
clonal antibody conjugated with phycoerythrin (PE;
Becton-Dickinson, Rutherford, NJ) and either an
anti-CD61 monoclonal antibody (DAKO, Carpen-
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teria, Calif) or an isotype-matched mouse IgG 
control antibody, both of which were conjugated 
with fluorescein isothiocyanate (FITC; DAKO,
Carpinteria, Calif). The samples were resuspended in
0.4 mL HT buffer and analyzed in an EPICS XL
flow cytometer (Coulter, Miami, Fla). Monocytes
were identified by means of CD14-positivity and
their characteristic orthogonal light-scattering prop-
erties. The percentage of platelet-leukocyte aggrega-
tion was determined by means of surface binding of
the platelet-specific CD61 antibody, within each
subpopulation of leukocytes, above that of the
mouse IgG control antibody. 
For leukocyte CD11b analysis, 20 m L of fresh,
whole blood was combined with 20 m L modified
HT buffer and 5 m L each of anti-CD14 monoclonal
antibody conjugated with PE and anti-CD11b
monoclonal antibody conjugated with FITC. After
10 minutes of incubation at room temperature, the
samples were fixed at 22°C for 10 minutes with 1%
formaldehyde and 1.4X Hanks balanced saline solu-
tion (GIBCO, Grand Island, NY). Samples were
diluted 10-fold with distilled H2O and incubated an
additional 10 minutes to allow lysis of the erythro-
cytes. Next, 0.5 mL HT buffer was added and the
samples were washed by centrifugation for five min-
utes at 500 g. All the supernatant except 20 m L was
discarded, and the remaining pellet was resuspended
with 0.5 mL HT buffer. Samples were immediately
analyzed in an EPICS XL flow cytometer.
The flow cytometer was equipped with a 500-mW
argon laser (Cyonics, San Jose, Calif), operated at 15
mW and a wavelength of 488 nm. The fluorescence
of FITC and PE were detected by using 525 nm and
575 nm band pass filters, respectively. Monocytes
were identified based on their characteristic side light
scatter and CD14-PE positivity. Neutrophils were
identified by their relative low CD14 binding and
their characteristic side light scatter. CD11b binding
is expressed as linear fluorescent units.
The 2-tailed Student t test was used to compare
results within and between groups, with statistical
significance accepted for P values less than .05.
Analysis of variance (ANOVA) was subsequently
performed, with Bonferroni’s t test, to test the null
hypothesis among all three groups simultaneously.
Again, significance was accepted for P values less
than .05.
RESULTS
Patients with venous insufficiency, as a group,
were older than the healthy control subjects (48.4 ±
14.4 years vs. 34.2 ± 7.4 years; P < .01). The older
group had a higher incidence of arterial hypertension,
but no other associated medical illnesses (Table I). 
According to the classification of venous insuf-
ficiency, four patients were clinical class 1, six
patients were class 2, two patients were class 3, two
patients were class 4, one patient was class 5, and
nine patients were class 6. All patients with venous
insufficiency studied by means of duplex scanning
had reflux rather than obstruction as their patho-
physiologic dysfunction, with 19 of 21 patients
having superficial reflux, 13 of 21 patients having
deep system reflux, and 11 of 21 patients having
both superficial and deep system reflux. Perforat-
ing veins were not consistently evaluated. The
duplex records of three of the patients with CVI
were not available for review. 
Patients with CVI had significantly more
platelet-monocyte aggregates in both the leg and
arm samples than did the healthy control subjects
([mean ± SEM]: 28.8% ± 3.4% vs. 7.7% ± 0.8%, P <
.0001). There were no significant differences
between leg and arm values within either group.
Furthermore, the addition of epinephrine, ADP, or
TRAP resulted in the formation of significantly
greater numbers of aggregates in patients with CVI
than in control subjects; again, no differences were
noted between arm and leg samples (Fig 1).
Table I. Study population demographics
Characteristic All patients Class 1 to 4 Class 5 to 6 Control subjects
Age (mean ± SEM) 48.4 ± 14.4 43.9 ± 11.2 53.7 ± 16.5 34.2 ± 7.4
Men 12 5 7 9
Women 12 9 3 6
Hypertension 5 2 3 0
Diabetes mellitus 1 0 1 0
Cardiac disease 0 0 0 0
Tobacco use 4 2 2 2
Current use of nonsteroidal 7 2 5 3
anti-inflammatory drugs
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When the patients with CVI were analyzed in
groups either with (n = 10) or without (n = 14) ulcer-
ation, no differences were noted in the percentages of
circulating aggregates at baseline or in the presence of
added agonist. Furthermore, there were no significant
differences in the percentages of heterotypic aggre-
gates in either the arm or the leg specimens (Fig 2).
These observations were confirmed by means of
Bonferroni’s ANOVA. Specifically, both CVI groups
had significantly more platelet-monocyte aggregates
at baseline and on the addition of agonist than did
control subjects. With the exception of the arm-
blood specimens in patients who had CVI with
ulceration at baseline, who had significantly more
platelet-monocyte aggregates than the patients who
had CVI without ulceration, there were no signifi-
cant differences in numbers of platelet-monocyte
aggregates in patients with or without ulceration in
the presence or absence of platelet agonists.
Although patients with venous insufficiency had
larger numbers of circulating platelet-neutrophil
aggregates than did healthy control subjects, these
values did not reach statistical significance (7.2 ± 1.4
vs. 3.6 ± 0.5; P = .05). Both epinephrine and TRAP
lead to the formation of more (but not significantly
more) platelet-neutrophil aggregates in patients with
CVI than in control subjects, whereas ADP led to sig-
nificantly more platelet-neutrophil aggregates in
patients with CVI. As with platelet-monocyte aggre-
gates, there were no significant differences between
heterotypic-aggregate levels in the arm or leg samples
of patients with CVI or control subjects (Fig 3). As
with the platelet-monocyte aggregates, these observa-
tions were borne out when all groups were observed
simultaneously by using Bonferroni’s ANOVA.
Leukocyte CD11b values, recorded in arbitrary
units, fell along a normal distribution curve when a
logarithmic scale was used. Monocyte CD11b
expression was significantly higher in both the leg
and arm blood of all patients with venous insuffi-
ciency than in that of control subjects. Monocyte
CD11b values were not different between arm and
leg samples in either control subjects or patients
with venous insufficiency. Furthermore, no differ-
ences were noted in monocyte CD11b values in the
leg or arm samples of patients in the presence or
absence of stasis ulceration (Figs 4 and 5). By means
of ANOVA, however, the surface expression of
monocyte CD11b was revealed to be statistically
greater in patients who had CVI with ulceration
than in control subjects, whereas the expression of
CD11b on the monocytes of patients with CVI but
with no ulceration was greater than in control sub-
jects, but did not achieve statistical significance.
No significant differences in neutrophil CD11b
Fig 1. Percentage of circulating monocytes with surface-
bound platelets (platelet-monocyte aggregates) at baseline
(none) and with the addition of different platelet agonists.
Control, healthy volunteer (n = 15); Patient, volunteer
with any degree of chronic venous insufficiency (n = 24).
*P < .001, patient vs. control subject. **P < .02, patient
vs. control.
Fig 2. Percentage of circulating monocytes with surface-
bound platelets (platelet-monocyte aggregates) at baseline
(none) and with the addition of different platelet agonists.
– ulcer, clinical classes 1 to 4 (n = 14); + ulcer, clinical class-
es 5 to 6 (n = 10).
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levels were noted in either the leg or arm blood
between patients who had CVI with or without
ulceration and control subjects, nor were there any
significant differences in CD11b values within the
venous insufficiency groups with or without ulcera-
tion (Figs 4 and 5). No statistically significant differ-
ences were noted when all three groups were evalu-
ated simultaneously by means of ANOVA.
DISCUSSION
Platelet-leukocyte aggregates have been described
in a variety of clinical situations, including stable
coronary artery disease,9 unstable angina,10 and
after the passage of blood through extracorporeal
circuits, including cardiopulmonary bypass graft-
ing11 and hemodialysis.12 It was Peyton et al who
first showed that these platelet-monocyte aggregates
are present in increased amounts in patients with
VSU.7 We have expanded this observation to show
that all clinical classes of venous insufficiency 
are associated with similar, significantly increased
levels of circulating platelet-monocyte aggregates.
Platelet-neutrophil aggregates are also increased
throughout the circulation in patients with CVI in
amounts that approach, but do not achieve, statisti-
cal significance. Although the small number of
patients in each clinical class of venous insufficiency
increases the possibility of a type-2 error, we con-
clude that platelets are activated to a similar degree
in all clinical classes of CVI and, as shown else-
where,13 these activated platelets have an increased
affinity for monocytes (relative to neutrophils).
Restated in clinical terms, the severity of CVI is not
predictive of the level of circulating heterotypic
aggregates. Furthermore, the presence of venous
ulceration does not cause platelet activation and
heterotypic-aggregate formation. Finally, these het-
erotypic aggregates are not sequestered in the
affected limbs of patients with CVI. 
The present study has also provided evidence of
enhanced platelet reactivity in patients with CVI.
Three platelet agonists, epinephrine, ADP, and
TRAP, each of which stimulates platelets by different
degrees and via different receptors,9 led to the for-
mation of progressively more platelet-monocyte
aggregates in patients with venous insufficiency than
in control subjects. This enhanced responsiveness
was observed to a similar degree in patients who had
CVI with and without ulceration, eliminating the
ulcer as the source of this excess reactivity. As a part
of our experiment (results not shown), we stimulat-
ed every sample with thrombin, the most potent
platelet agonist,8 as a positive control. We observed a
similar, almost complete (more than 95%) platelet-
monocyte–aggregate formation in all patients with
CVI as well as in controls, indicating that the
platelets in control subjects were capable of complete
activation. This supports our theory that enhanced
platelet responsiveness to submaximal physiologic
stimulation in CVI, as reflected by heterotypic-aggre-
gate formation, represents a state of platelet hyperre-
activity. The cellular mechanisms responsible for
priming these platelets remain unknown. 
The role of heterotypic aggregates in the patho-
genesis of CVI remains under investigation. It is
plausible that circulating heterotypic aggregates are
complexes that are capable of injuring venous
endothelium and valves, leading to the develop-
ment of venous valvular dysfunction. Leukocytes,
when activated, produce reactive oxygen species,
chemoattractant (eg, IL-8), hydrolases, arachidonic
acid metabolites, and platelet-activating factor.14 It
is known that activated platelets, through P-
selectin, induce monocyte tissue factor (a co-factor
for factor VII),15 chemotactic protein-1, and the
cytokines interleukin-1 b and tumor necrosis factor-
a.
14,16,17 Interleukin-1 and tumor necrosis factor- a
both act on endothelial cells to increase leukocyte
adhesion.18,19
Fig 3. Percentage of circulating neutrophils with surface-
bound platelets (platelet-neutrophil aggregates) at base-
line (none) and with the addition of different platelet ago-
nists. Control, healthy volunteer (n = 15); Patient, volun-
teer with any degree of chronic venous insufficiency (n =
24). *P < .04, patient vs. control.
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CD11b is the alpha subunit of the beta2 integrin
surface heterodimer Mac-1 that is expressed on cir-
culating leukocytes. Mac-1 is a member of the larg-
er beta integrin family of leukocyte adhesion recep-
tors, which have a common beta subunit (CD18)
and a distinct alpha subunit (CD11a, CD11b, and
CD11c).20 These receptors promote adhesion of
monocytes and neutrophils to endothelial cells,
extracellular matrix, and components of the comple-
ment cascade.14 Binding of CD18/CD11b to its
complementary endothelial receptors intercellular
adhesion molecule (ICAM-1) and endothelial
leukocyte adhesion molecule (ELAM-1)18,21 per-
mits subsequent diapedesis through endothelial
cells.22,23 CD11b levels are expressed constitutively
at relatively low levels on circulating quiescent
leukocytes.24 With leukocyte activation, surface lev-
els of CD11b increase markedly.14,25
The beta subunit of the Mac-1 receptor has
other functions in addition to intracellular adhesion.
In fact, neutrophil CD11b is believed to be a pre-
dominantly proinflammatory receptor, active in the
oxidative burst necessary for cell killing. Monocyte
CD11b, however, is believed to have a procoagu-
lant, rather than inflammatory, role.20
Patients with lipodermatosclerosis and VSU
have significantly more monocytes in the skin 
of their affected extremities than patients with 
less clinically severe venous insufficiency.26 The
endothelial cells of patients with clinically advanced
venous disease have increased expression of mono-
cyte, but not neutrophil, adhesion molecules,26,27
further implicating monocytes as the leukocyte
responsible for the pathogenesis of clinically
advanced CVI. Finally, the role of monocytes in the
genesis of primary venous dysfunction by valve
destruction28 has been clearly identified. Our
results further support the involvement of activated
monocytes in venous insufficiency.
We observed that patients with CVI had
increased levels of circulating activated monocytes,
as reflected by increased surface expression of
CD11b. The differences were significant between
control subjects and patients with ulceration and
were not significant within CVI groups (with or
without ulceration) or between control subjects and
patients who had CVI without ulceration. Our data
suggest that monocyte activation cannot be
explained by active stasis ulceration or experimental-
ly induced venous hypertension. Although the pres-
ence of activated monocytes in the circulation of
patients with CVI precedes the development of sta-
sis ulceration, their presence is not predictive of dis-
ease stage or potential for disease progression. 
As with the heterotypic aggregates, not all of the
activated monocytes in patients with CVI were
sequestered in the lower extremities. In fact, no dif-
ferences were noted in monocyte CD11b surface
expression in arm or leg samples. The role of these
circulating, activated monocytes in the pathogenesis
of CVI warrants further investigation. 
Neutrophil CD11b levels were no different
between control subjects and patients with venous
insufficiency. Although it is possible that all activat-
ed neutrophils were bound in the microcirculation
of limbs with CVI, the obvious discrepancy between
circulating activated monocytes and leukocytes
makes this an unlikely explanation. The absence of
neutrophil activation in CVI has been noted by
other authors,3 and, despite their previously men-
tioned proinflammatory role, it is much more likely
that activated neutrophils do not assume a signifi-
cant role of the pathogenesis of CVI. 
Whether venous dysfunction occurs as a result of
Fig 4. Relative CD11b fluorescence of monocytes and
neutrophils in control subjects (n = 15) and patients (n =
24). *P < .01, patient vs. control.
Fig 5. Relative CD11b fluorescence of monocytes and
neutrophils in patients who have chronic venous insuffi-
ciency with (n = 10) and without ulceration (n = 14).
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obstruction (secondary) or unknown cause (prima-
ry), ambulatory venous hypertension results. All the
patients in our study had experimentally induced
venous hypertension, yet this was not an adequate
stimulus to induce platelet or monocyte activation in
patients without reflux. Clearly, reflux plays a role in
the development of ambulatory venous hyperten-
sion. It may also play a role in platelet and monocyte
activation. 
We did not study patients with acute venous
obstruction that was a cause of venous insufficiency,
although two patients did give a remote history of
deep vein thrombosis. The patterns of venous reflux
we observed are consistent with the observations of
others: its presence correlates with venous disease; it
may exist without obvious venous disease; and, in
general, superficial system reflux is more prevalent
than deep system reflux.29 Furthermore, superficial
reflux contributes to the development of venous
ulceration at least as often as deep system reflux.30
Whether circulating heterotypic aggregates, activated
monocytes, or both contribute to the development
of reflux, or vice versa, with subsequent variable pro-
gression of venous disease, remains to be shown. 
In summary, we have demonstrated that CVI is
associated with increased platelet and monocyte acti-
vation and aggregation throughout the circulation.
Increased platelet-neutrophil aggregation also
occurs, although we found no evidence of increased
neutrophil activation (as reflected by surface CD11b
expression). The stimulus for platelet and monocyte
activation and the explanation for platelet hyperreac-
tivity are, as yet, unknown. What also remains to be
shown is the degree to which these heterotypic
aggregates communicate with each other and with
the endothelium. 
Because platelets bind monocytes and neu-
trophils by the same receptors,31,32 it is difficult to
attribute the differential activation of monocytes and
neutrophils, as reflected by surface CD11b expres-
sion, in CVI solely to the binding of activated
platelets, unless different signals are sent by activat-
ed platelets to monocytes and neutrophils or the
response of these cells to activated platelets is differ-
ent. Such a study is beyond the scope of this work. 
We did observe a significant age difference
between control subjects and patients with CVI. Age
has been shown to be an independent risk factor for
the development of VSU.33 It is, therefore, not sur-
prising that the patients in our CVI group were
older. What remains to be answered is whether
patient age affects platelet and monocyte activation.
Although the presence of platelet-leukocyte
aggregates throughout the circulation may simply be
as a nonspecific marker of venous valvular reflux, the
possibility that platelet-leukocyte aggregates repre-
sent a fundamental derangement in CVI is an
intriguing one. Still, if circulating platelet-leukocyte
aggregates do play a role in the development and
progression of CVI, it remains to be shown why sim-
ilar levels of circulating aggregates exist in patients
with very different degrees of clinical disease severi-
ty and why these aggregates are present in similar
percentages throughout the circulation, whereas the
clinical manifestations of the disease are most preva-
lent in the legs. Identification of the stimulus (or
stimuli) for platelet activation and the cause for
increased platelet responsiveness to agonists and
identification of any proinflammatory or procoagu-
lant signals unique to platelet-leukocyte aggregates
in CVI may further our understanding of the devel-
opment and progression of venous insufficiency and
potentially open new avenues in the prevention and
treatment of this prevalent and frequently disabling
disorder.
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Dr Peter J. Pappas (Worcester, Mass). This presenta-
tion by Dr Powell represents the second investigation on
the relationship between platelet monocyte aggregation
and chronic venous insufficiency by the University of
Massachusetts group. In their first investigation, they
reported an increase in platelet-monocyte aggregates in
patients with venous ulceration, compared with healthy
control subjects. This presentation tries to determine if
this observation is caused by disease factors associated with
chronic venous insufficiency or the inflammatory reaction
caused by the presence of the venous ulcer. After review-
ing the manuscript and listening to this presentation, I am
not sure whether they answered the question.
The current study separated patients into three
groups. Group one consisted of healthy patients (n = 15),
as defined by means of the absence of reflux on a duplex
examination. Group two consisted of patients who had
chronic venous insufficiency with a CEAP class of 1
through 4 (n = 14), and group three consisted of patients
with active ulcers (n = 9 and n = 1, respectively). The
authors state that all the patients with chronic venous
insufficiency had increased platelet-monocyte aggregates
at rest and with agonist stimulation, compared with con-
trol subjects. They also noted an increase in aggregates in
blood samples taken from the antecubital arm veins and
increased CD11b expression on circulating monocytes.
However, no differences among the CVI groups were
identified.
I have several serious concerns with these conclusions,
based on how the statistical analyses were performed, and
with the scientific methods. Based on these concerns, I
have several questions for the authors.
The authors used flow cytometry as a means of deter-
mining the percentage of cells that demonstrated platelet-
monocyte binding and linear intensity units as means of
quantifying the number of CD11b receptors on mono-
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cytes and neutrophils. Anyone who has ever used flow
cytometry knows that the Achilles’ heel of this technique
is measurement variability and reproducibility. For exam-
ple, linear intensity varies based on the amount of time the
antibody has been bound before measurement and differ-
ences in fluorescence between antibody lots. To normalize
for this expected variability, two methods are normally
used. You can calibrate the flow cytometer against a bead
with a known intensity and adjust the cytometer according
to the standard. The second method is developing a loga-
rithmic regression curve with several beads of known
intensity and then measuring your samples on the devel-
oped standard curve. No mention of this normalization or
standardization technique was presented in the methods
section of the manuscript. These normalization techniques
are mandatory to minimize the day-to-day variability
inherent with these types of measurements. Similarly, did
you measure your total leukocyte count in each patient
and normalize your aggregation measurements to the
total number of platelets, monocytes, and neutrophils per
patient? I believe the answers to these questions are criti-
cal. If no standardization process was used, then the accu-
racy of your measurements is in doubt.
My second question relates to how you performed
your statistical analyses. In the current study, the authors
had three study groups, as previously mentioned. The
patients with class 1 through 4 disease were crucial to
answering the central question: Is increased platelet
monocyte aggregation caused by chronic venous insuffi-
ciency or inflammatory processes associated with venous
ulceration? To answer this question, the patients with
chronic venous insufficiency and ulcers need to be com-
pared with healthy control subjects. This is typically done
by performing an analysis of variance and a nonparametric
post-hoc test, such as the Student t test, when the analysis
of variance is positive.
Instead, the authors combined all the patients with
chronic venous insufficiency, compared them with control
subjects, and proceeded to use a two-tail t test. They clear-
ly had enough patients in each group to do a subgroup
analysis, so my second question for the authors is have you
done this subgroup analysis? Are there significant differ-
ences between classes 1 through 4 patients and control
subjects?
My third question relates to the three patients with
clinical chronic venous insufficiency and normal findings
on duplex examinations. Did these patients really have
chronic venous insufficiency? Since the development of
our venous clinic at the New Jersey Medical School, I have
examined several patients who had normal findings on
duplex examinations and clinical evidence of chronic
venous insufficiency. Most of these patients have calf mus-
cle pump dysfunction, as demonstrated by means of air
plethysmography. The remainder have dermatologic dis-
eases. So, what class disease did these three patients have?
If you eliminate them from your analysis, do your results
change?
Finally, my last question relates to the significance of
platelet monocyte aggregates. As was pointed out in the
manuscript, platelet-monocyte aggregates form in patients
undergoing coronary artery bypass grafting with the
pump oxygenator. This leads to bleeding problems in
these patients, and as a result, many centers now sequester
the patients’ platelets before they go on bypass and
retransfuse them at the completion of the case, which
results in fewer bleeding problems. So, what is the signifi-
cance of platelet-monocyte aggregation in patients with
chronic venous insufficiency? Is it involved in the patho-
genesis of chronic venous insufficiency, or are your obser-
vations just phenomenology?
I enjoyed reading the manuscript. I find the concept
of platelet monocyte interactions interesting and encour-
age the authors to continue their investigations. Thank
you.
Dr Craig C. Powell. Thank you, Dr Pappas. A critical
and objective interpretation of presented work is necessary
to either validate that work or expose it as potentially
flawed, and I hope to be able to do the former by answer-
ing your questions.
The Center for Platelet Function Studies at the
University of Massachusetts Medical Center, which is
headed by Drs Michelson, Rohrer, and Furman, has a rep-
utation that has been established by meticulous attention
to detail and reproducibility of results. Our XL flow
cytometer is calibrated daily for alignment by using DNA
check beads, the former of the two methods of validation
that you asked about. We also undertake daily cleansing
and monthly maintenance of the machine, and any drift
that is identified in bead fluorescence necessitates any set-
ting adjustments. Because of the meticulous attention to
detail on the machine, setting adjustments are rarely need-
ed, so daily validation with flow beads was performed.
Using our flow cytometer, we measured the percent-
age of circulating subgroups of each of the leukocyte pop-
ulations: monocytes, neutrophils, and lymphocytes.
Although we did not record actual numbers, we found
that the percentages within each subgroup were about the
same: 55% to 60% neutrophils, 5% to 8% monocytes, and
the rest lymphocytes. Our results were reported as a per-
centage of these circulating cells with bound platelets, so
the absolute values of bound aggregates were not as
important as the percentage of circulating cells.
We did use a two-tail t test, and we evaluated two
groups at a time, because we were trying to prove whether
the increased significant numbers of circulating heterotyp-
ic aggregates in venous insufficiency were a response to
ulceration or if it was present in all groups. In the manu-
script, I just presented classes 1 to 4 versus 5 and 6 and
found no significant difference. Your question is still a
good one: What about the controls versus classes 1 to 4?
Although it is not presented in the manuscript, I do have
that information, and there is a significant difference, with
a P value of less than 104 for circulating heterotypic aggre-
gates in the lesser clinical classes versus healthy control
patients.
You asked about three patients who had normal find-
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ings with duplex examinations. Actually, three of the 24
patients with venous insufficiency did not have duplex
results that I could find in our vascular laboratory, so I was
unable to comment on the degree of reflux that they had.
None of the patients with venous insufficiency had normal
findings on their duplex scans, however.
Finally, with regard to the significance of this process,
that is obviously the next question. We set out only to dis-
cover whether this increased platelet activation, which is
what the significance of heterotypic aggregates really is, is
present in all stages of venous insufficiency. The next ques-
tion obviously becomes, do they play a role or are they a
nonspecific marker? We know that P-selectin, PSGL1, and
CD11b are all integrins. They are cell surface adhesion
molecules that are not only involved in cell binding, but
also in cell-cell signaling, and it is quite probable, although
it will require much more work on the cellular level, that
different messages are being sent by these circulating
aggregates that may play a very important role in the
development and progression of the disease.
Dr Kevin Burnand (London, England). Have you
looked at the instance of earlier thrombosis in your
patients with chronic venous insufficiency and have you
also looked at the thrombophilia status of all your patients
with chronic venous insufficiency? Because it is attractive
to think that this might be egg, rather than chicken. The
final group that would be very interesting to look at would
be patients who have had a venous thrombosis and to dif-
ferentiate those patients who develop skin changes from
those who do not in a period that might give you an
answer as to whether this is important etiologically.
Dr Powell. Thank you. We did look at the background
of these patients with regard to the etiology of their
venous insufficiency. Of our 24 patients, only two had a
known history of deep vein thrombosis, the rest had
reflux, which they knew about. And again, a lot of patients
probably have venous obstruction and they don’t know
about it. CD11b, an integrin, has been shown to be
involved in cell-cell signaling. As mentioned in the manu-
script, monocyte CD11b (but not neutrophil CD 11b)
has been associated with a prothrombotic state. The rele-
vance of increased circulating CD11b may be the presence
of an as-yet incompletely identified prothrombotic state.
Patients may have microthrombosis and not know about
it. These patients are showing up in our offices years later
with venous insufficiency of various degrees.
